Randox are pleased to announce the acquisition of Cellix Limited, a Dublin-based company that develops microfluidic tools and impedance flow cytometers for cell analysis.
This acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space aligning with their commitment to personalised medicine and improved preventative healthcare.
Dr. Peter FitzGerald, Managing Director of Randox Laboratories:
“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians.”
“We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows resulting in better outcomes for patients.”
Vivienne Williams, CEO of Cellix:
“Our team is very excited to be joining forces with Randox to scale access to our technology in the broader scientific community.
“Cellix’s dedicated team has worked hard developing impedance-based cytometry for cell analysis supported through programs including the Disruptive Technology Innovation Fund. With Randox’s strong global presence and dedication to R&D, we are looking forward to continuing development of our technology and expanding our customer footprint.”